Abstracts tagged "Systemic sclerosis"

Abstract Number: 766 • 2014 ACR/ARHP Annual Meeting
Endothelial Fli1 Deficiency Delays Wound Healing Due to Impaired Anastomosis of Newly Formed Vessels – a Possible Mechanism of Refractory Skin Ulcers in Systemic Sclerosis
Yoshihide Asano¹ and Maria Trojanowska², ¹Dermatology, University of Tokyo Graduate School of Medicine, Tokyo, Japan, ²Arthritis Center, Boston University, Boston, MA
Background/Purpose Systemic sclerosis (SSc) is a multisystem inflammatory and vascular disease resulting in fibrosis of the skin and certain internal organs. Although the pathogenesis of…
Abstract Number: 740 • 2014 ACR/ARHP Annual Meeting
Right Ventricular Diastolic Impairment Is Common in Systemic Sclerosis and Is a Marker of Several Organ-Target Damage of the Disease
Christophe Meune¹, Dinesh Khanna², Jamil Aboulhosn³, Jerome Avouac⁴, Andre Kahan⁵, Daniel E. Furst⁶ and Yannick Allanore⁴, ¹Paris 13 University, University Hospital of Paris-Seine-Saint-Denis, Cardiology Department, Bobigny, France, ²University of Michigan Health System, Ann Arbor, MI, ³Department of Medicine, David Geffen School of Medicine at UCLA, Los Angeles, CA, ⁴Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ⁵Paris Descartes University, Rheumatology A department, Cochin Hospital, Paris, France, ⁶University of California, Los Angeles, Department of Medicine, Los Angeles, CA
Background/Purpose Heart failure and cardiac dysfunctions both of intrinsic or secondary origin and targeting LV (left ventricule) and/or RV (right ventricule) are critical complications promoting…
Abstract Number: 2603 • 2013 ACR/ARHP Annual Meeting
Are There Differences In Limited Systemic Sclerosis According To Extension Of Skin Involvement?
Marina Scolnik¹, Eliana Lancioni², Luis J. Catoggio¹, Mirtha Sabelli³, Zaida Bedran⁴, Carla Saucedo⁴, Josefina Marin³ and Enrique Soriano¹, ¹Rheumatology Section, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ²Rheumatology Unit, Internal Medicine Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ³Rheumatology Unit, Internal Medicine Service, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina, ⁴Rheumatology Unit, Internal Medical Services, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina
Background/Purpose: There is consensus in classifying Systemic Sclerosis (SSc) according to extension of skin involvement as limited and diffuse, using the elbows and knees as…
Abstract Number: 2579 • 2013 ACR/ARHP Annual Meeting
Recommendations For Screening and Detection Of Connective-Tissue Disease Associated Pulmonary Arterial Hypertension
Dinesh Khanna¹, Heather Gladue², John D. FitzGerald³, Richard N. Channick⁴, Lorinda Chung⁵, Oliver Distler⁶, Daniel Furst⁷, Eric Hachulla⁸, Marc Humbert^9,10,11, David Langleben^12,13, Stephen C. Mathai¹⁴, Rajeev Saggar¹⁵, Scott H. Visovatti¹⁶ and Vallerie McLaughlin¹⁷, ¹Division of Rheumatology, University of Michigan Medical Center, Ann Arbor, MI, ²University of Michigan, Ann Arbor, MI, ³Medicine/Rheumatology, UCLA School Med Rehab #32-59, Los Angeles, CA, ⁴Pulmonary Hypertension Program, Massachusetts General Hospital, Boston, MA, ⁵Rheumatology, Stanford Univ Medical Center, Palo Alto, CA, ⁶Division of Rheumatology, University Hospital Zurich, Zurich, Switzerland, ⁷Rheumatology, University of California in Los Angeles, Los Angeles, CA, ⁸Department of Internal Medicine, Claude Huriez University Hospital, Lille, France, ⁹AP-HP Hôpital Antoine Béclère, Clamart, France, ¹⁰Université Paris-Sud, Le Kremlin-Bicêtre, France, ¹¹NSERM U999, Centre Chirurgical Marie-Lannelongue, Le Plessis-Robinson, France, ¹²Cardiology Division, Jewish General Hospital, Montreal, QC, Canada, ¹³McGill University, Montreal, QC, Canada, ¹⁴Medicine, Johns Hopkins University, Baltimore, MD, ¹⁵Critical Care Medicine, St. Joseph's Hospital and Medical Center, Phoenix, AZ, ¹⁶Internal Medicine, Division of Cardiology, The University of Michigan, Ann Arbor, MI, ¹⁷Internal Medicine, Division of Cardiology, University of Michigan, Ann Arbor, MI
Background/Purpose: Pulmonary arterial hypertension (PAH) affects up to 15% of patients with connective tissue diseases (CTD) and is one of the leading causes of mortality…
Abstract Number: 2562 • 2013 ACR/ARHP Annual Meeting
Inhibition Of SOX9 Phosphorylation Abrogates The Increased Expression Of Profibrotic Genes In Systemic Sclerosis Dermal Fibroblasts
Sonsoles Piera-Velazquez, Alma Makul and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center,Thomas Jefferson University, Philadelphia, PA
Background/Purpose: SOX9, a high mobility group transcription factor is a master regulator of chondrogenesis and plays a crucial role in the regulation of chondrocyte gene…
Abstract Number: 2566 • 2013 ACR/ARHP Annual Meeting
Nilotinib Treatment Effect In The Skin As Measured By DNA Microarray In Patients With Diffuse Systemic Sclerosis
Jessica K. Gordon¹, Tammara A. Wood², Robert F. Spiera¹ and Michael L. Whitfield², ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, NH
Background/Purpose: Gene expression profiling by DNA microarray is used to identify potential biomarkers in Systemic Sclerosis (SSc). Discrete gene expression signatures have been observed to…
Abstract Number: 825 • 2013 ACR/ARHP Annual Meeting
Activating Transcription Factor 3 Regulates Canonical Transforming Growth Factor Beta Signaling In Experimental Fibrosis
Tatjana Mallano¹, Katrin Palumbo-Zerr¹, Christian Beyer¹, Clara Dees¹, Jingang Huang¹, Tsonwin Hai², Georg A. Schett³ and Joerg H. W. Distler¹, ¹Department of Internal Medicine III and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ²The Ohio State Biochemistry Program, The Ohio State University, Columbus, USA, Colombus, OH, ³Dept of Medicine 3, Rheumatology and Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany
Background/Purpose: Activating transcription factor 3 (ATF3), a member of the activating transcription factor/cAMP-responsive element binding protein (ATF/CREB) family of transcription factors is induced by various…
Abstract Number: 709 • 2013 ACR/ARHP Annual Meeting
Nilotinib (Tasigna™) In The Treatment Of Early Diffuse Systemic Sclerosis: A Single Group, Open Label Pilot Clinical Trial – One Year Results
Jessica K. Gordon¹, Cynthia Magro², Uzunma Udeh¹, Daniele Lerner¹, Horatio F. Wildman³, Wei-Ti Huang⁴, Mary K. Crow⁵ and Robert F. Spiera¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Dermatopathology, Weill-Cornell Medical Center, New York, NY, ³Dermatology, Weill-Cornell Medical Center, New York, NY, ⁴Biostatistics, Hospital for Special Surgery, New York, NY, ⁵Department of Medicine, Hospital for Special Surgery, New York, NY
Background/Purpose: Tyrosine kinase inhibitors (TKI) are under investigation for the treatment of diffuse cutaneous Systemic Sclerosis (dcSSc.) Nilotinib is a second-generation TKI which selectively antagonizes c-abl and…
Abstract Number: 676 • 2013 ACR/ARHP Annual Meeting
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease
Gabriele Valentini¹, Antonella Marcoccia², Michele Iudici³, Serena Vettori¹ and Giovanna Cuomo³, ¹Department of Clinical and Experimental Medicine, Rheumatology Unit, Second University of Naples, Naples, Italy, ²Angiology Unit, Sandro Pertini Hospital, Rome, Italy, ³Department of Internal and Experimental Medicine, Second University of Naples, Naples, Italy
Background/Purpose: To investigate whether patients affected with any of the 3 subsets of early systemic sclerosis (SSc) i.e. Raynaud’s Phenomenon (RP) with SSc marker autoantibody…
Abstract Number: 683 • 2013 ACR/ARHP Annual Meeting
HRCT Predictors Of Decline In FVC% predicted—Implications For Cohort Enrichment For Scleroderma Lung Disease (SLD) Trials
Dinesh Khanna¹, Chi-hong Tseng², Robert D. Suh³, Fereidoun Abtin⁴, Athol U. Wells⁵, Donald Tashkin⁶ and Jonathan Goldin⁷, ¹University of Michigan, Ann Arbor, MI, ²Medicine, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA, ³UCLA Department of Radiological Sciences, Ronald Reagan UCLA Medical Center, Los Angeles, CA, ⁴Radiology, University of California Los Angeles Medical Center, Santa Monica, CA, ⁵Royal Brompton and Harefield NHS Foundation Trust, Department of Radiology, London, United Kingdom, ⁶Medicine, University of California at Los Angeles, Los Angeles, CA, ⁷Radiology, University of California, Los Angeles, David Geffen School of Medicine, Los Angeles, CA
Background/Purpose: Moderate-to-severe HRCT-defined lung involvement (total lung involvement or fibrosis) is a predictor of decline in FVC% predicted and mortality in SLD. Various staging systems…
Abstract Number: 686 • 2013 ACR/ARHP Annual Meeting
Blood Flow In The Hands Of a Predefined Homogeneous Systemic Sclerosis Population: The Presence Of Digital Ulcers and The Improvement With Bosentan
Jessica Meijs¹, Annemie J.M. Schuerwegh¹, Alexandre E. Voskuyl², Joanne P.J. Bloemsaat-Minekus³ and Madelon C. Vonk⁴, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ³Actelion, Woerden, Netherlands, ⁴Department of Rheumatology, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands
Background/Purpose: Digital ulcers (DU) are complications of systemic sclerosis (SSc) and arise as a result of ischaemia due to vasculopathy of the digital arteries (1).…
Abstract Number: 652 • 2013 ACR/ARHP Annual Meeting
Pirfenidone and BIBF1120 Suppress Collagen Synthesis In Skin Fibroblast From Patients With Systemic Sclerosis
Yuko Ota¹, Yasushi Kawaguchi¹, Kae Takagi¹, Hisae Ichida¹, Yasuhiro Katsumata¹, Takahisa Gono¹, Yuko Okamoto¹, Tomoaki Higuchi², Hidenaga Kawasumi¹ and Hisashi Yamanaka¹, ¹Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, ²Institute Of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan
Background/Purpose: Pirfenidone (5-methyle-1-phenyl-2- [1H]-pyridone) and BIBF1120 (Nintedanib) are currently evaluated in clinical trials as a potential idiopathic pulmonary fibrosis (IPF). Pirfenidone was approved as the…
Abstract Number: 2919 • 2013 ACR/ARHP Annual Meeting
The Clinical Utility Of Flow-Mediated Dilation In Systemic Sclerosis
Tracy M. Frech¹, Ashley Walker², Zachary Barrett-Okeefe², Russell Richardson², D. Walter Wray² and Anthony Donato², ¹Internal Medicine, Salt Lake City VAMC, Salt Lake, UT, ²University of Utah, Salt Lake, UT
Background/Purpose: In systemic sclerosis (SSc, scleroderma) vasculopathy can result in the end-stage manifestation of a digital ulcer (DU). We hypothesized that bedside flow mediated dilatation…
Abstract Number: 2594 • 2013 ACR/ARHP Annual Meeting
Stabilisation Of Microcirculation In Early Systemic Sclerosis Patients With Diffuse Skin Involvement Following Rituximab Treatment
Vanessa Smith¹, Carmen Pizzorni², Valeria Riccieri³, Saskia Decuman⁴, Yves P. Piette¹, Ellen Deschepper⁵, Filip De Keyser¹ and Maurizio Cutolo⁶, ¹Department of Rheumatology, Ghent University Hospital, Ghent, Belgium, ²Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine, University of Genova, Genoa, Italy, ³Department of Internal Medicine and Medical Specialities, University Sapienza, Rome, Italy, ⁴Department of Internal Medicine, Ghent University, Ghent, Belgium, ⁵Biostatistics Unit, Department of Public Health, Ghent University, Ghent, Belgium, ⁶University of Genova, Genova, Italy
Background/Purpose: Microangiopathy in systemic sclerosis is progressive over time [1, 2]. This study assesses microangiopathic evolution by nailfold videocapillarocopic (NVC) analysis after two treatment course…
Abstract Number: 2599 • 2013 ACR/ARHP Annual Meeting
Safety and Effectiveness Of Mycophenolate In Systemic Sclerosis: A Systemic Review
Mohammed Omair¹, Abdulaziz Alahmadi² and Sindhu R. Johnson³, ¹Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ²Medicine, Toronto Scleroderma Research Program, Division of Rheumatology, Mount Sinai Hospital, Toronto Western Hospital, University Health Network, University of Toronto, Toronto, ON, Canada, ³Medicine, Toronto Western Hospital, Toronto General Hospital, Mount Sinai Hospital, and University of Toronto, Toronto, ON, Canada
Background/Purpose: Mycophenolate reduces chronic allograft nephropathy and interstitial fibrosis by inhibiting TGF-β, which is an important molecule in the pathogenesis of systemic sclerosis (SSc). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].